Treatment of Chronic Radial Epicondylitis with Botulinum Toxin A

Placzek, Richard; Drescher, Wolf; Deuretzbacher, Georg; Hempfing, Axel; Meiss, A. Ludwig
February 2007
Journal of Bone & Joint Surgery, American Volume;Feb2007, Vol. 89-A Issue 2, p255
Academic Journal
Background: Radial epicondylitis (tennis elbow) is the most frequent type of myotendinosis. Patients can experience substantial loss of function, especially when this condition becomes chronic. A successful therapy has not yet been established. A preliminary study of injections of botulinum toxin A in patients with chronic epicondylitis has shown promising results. Methods: In the present prospective, controlled, double-blinded clinical trial, 130 patients were examined at sixteen study centers. A single injection of botulinum toxin A into the painful origin of the forearm extensor muscles was per- formed. Follow-up examinations were performed at two, six, twelve, and eighteen weeks. Clinical findings were documented with use of a new clinical pain score and with a visual analogue scale. A global assessment of the result of treatment was also provided by the patient and the attending doctor. Strength of extension of the third finger and the wrist was evaluated with use of the Brunner method, and grip strength (fist closure strength) was measured with a vigorimeter. Results: The group treated with botulinum toxin A was found to have a significant improvement in the clinical findings, compared with those in the placebo group, as early as the second week after injection (p = 0.003). Subjective general assessment also showed improvement in that group, compared with the placebo group, at six weeks (p = 0.001) and at the time of the final examination (at eighteen weeks) (p = 0.001). There was a consistent increase in fist closure strength in both the group treated with botulinum toxin A and the control group, but there was no significant difference between groups. As was expected as a side effect, extension of the third finger was observed to be significantly weakened at two weeks but this complication had completely resolved at eighteen weeks. Conclusions: We concluded that local injection of botulinum toxin A is a beneficial treatment for radial epicondylitis (tennis elbow). The treatment can be performed in an outpatient setting and does not impair the patient's ability to work.


Related Articles

  • Botulinum toxin in the management of acquired motor fusion deficiency. Murthy, Ramesh; Kesarwani, Siddharth // Indian Journal of Ophthalmology;Dec2009, Vol. 57 Issue 6, p463 

    Acquired disruption of motor fusion is a rare condition characterized by intractable diplopia. Management of these patients is extremely difficult. Prisms in any combination or even surgery may not help relieve their symptoms. We describe a longstanding case of acquired motor fusion disruption...

  • Single-session Botox safe, effective. Guttman, Cheryl // Dermatology Times;Apr2005 Supplement 2, Vol. 26, pS14 

    The article presents information related to Botulinum toxin type A (Botox, Botox Cosmetic; Allergan). Botox can be used safely and effectively in a range of doses to simultaneously treat a spectrum of upper facial rhytids in adult women, although use of a higher dose affords benefits for...

  • Household Biowaste Containers (Bio-Bins) — Potential Incubators For Clostridium Botulinum and Botulinum Neurotoxins. Böhnel, Helge // Water, Air & Soil Pollution;Oct2002, Vol. 140 Issue 1-4, p335 

    In previously conducted research, Clostridium botulinum spores were found in bio-waste compost. Household bio-waste, collected in `bio-bins', was suspected to be one of the reasons for contamination. Maggots of Calliphoridae were collected inside and outside of bio-bins from 8 different...

  • Botulinum Toxin for Suspected Pseudoachalasia. Vallera, Raymond A.; Brazer, Scott R. // American Journal of Gastroenterology;Aug1995, Vol. 90 Issue 8, p1319 

    We describe a 74-yr-old man with stage III adenocarcinoma of the lung who presented with suspected malignancy-induced secondary achalasia and responded clinically to intrasphincteric injections of botulinum toxin type A (Botox, Allergen Inc., Irvine, CA). We discuss the use of botulinum toxin in...

  • Toxina botulínica para la secreción descontrolada de saliva: Presentación de un caso. DI NASSO, Patricia; BACCO RODRIGUEZ, José Luis; MANSILLA MONTENEGRO, Julio // Revista de la Facultad de Odontología. Universidad Nacional de ;2010, Vol. 4 Issue 1, p39 

    The botulinum neurotoxin is produced by the anaerobic bacterium clostridium botulinum (BoNT). It blocks neuromuscular transmission and for this reason it's used to treat diseases with muscular hyperactivity by blocking acetylcholine release and thus synaptic transmission at the neuromuscular...

  • Restraint helps avoid filler pitfalls. Jesitus, John // Dermatology Times;Sep2005, Vol. 26 Issue 9, p106 

    Focuses on the use of botulinum toxin as a complementary treatments for facial rejuvenation. Indications for botulinum toxin; Complications of the treatment; Recommendations on the administration of botulinum toxin.

  • Botulinum Toxin in Medical Therapy. Skorin Jr., Leonid // Review of Optometry;7/15/2004, Vol. 141 Issue 7, p53 

    Focuses on the use of botulinum toxin in medical therapy in the U.S. Treatment of blepharospasm, strabismus, and other ocular muscle disorders; Inhibition of the release of acetylcholine from the nerve terminal; Availability of two immunologically distinct neurotoxins for clinical use in the...

  • Crow's Feet Treatment with Botulinum Toxin Type A. Petropoulos, I.; Noussios, G.; Chouridis, P.; Kontzoglou, G.; Karagiannidis, K. // Internet Journal of Aesthetic & Antiaging Medicine;Oct2008, Vol. 1 Issue 2, p1 

    Botulinum toxin type A is widely used for treatment of facial rhytids, often in an "off-label" fashion. The most important mechanisms of action and safety concerns for such treatments are presented, with recommendations for treatment of periorbital rhytids.

  • Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Dressler, Dirk; Bigalke, Hans; Benecke, Reiner // Journal of Neurology;Aug2003, Vol. 250 Issue 8, p967 

    Recently, it was reported that botulinum toxin type B complex (BoNT/B) (NeuroBloc®, Elan Pharmaceuticals) can produce an adequate therapeutic response in patients with antibody induced failure of botulinum toxin type A complex (BoNT/A) therapy. We wanted to study whether this effect is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics